Comparison · NCT04508023-bf7c2edc
Rivaroxaban 10 Milligrams (mg) vs Placebo: Number of Participants With Time to First Occurrence of Primary Efficacy Composite Endpoint
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Rivaroxaban 10 Milligrams (mg) vs Placebo: Number of Participants With Time to First Occurrence of Primary Efficacy Composite Endpoint. Trial comparisons, record NCT04508023-bf7c2edc. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04508023-bf7c2edc
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0343 | 0.0228 | 0.0514 | wilson | |
| Risk in group 2 | 0.0295 | 0.019 | 0.0457 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00477 | -0.0151 | 0.0249 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.16 | 0.635 | 2.12 | log | |
| Odds ratio, group 1 over group 2 | 1.17 | 0.626 | 2.18 | log | |
| Number needed to treat, for one more participant with the outcome on Rivaroxaban 10 Milligrams (mg) than on Placebo | 210 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Rivaroxaban 10 Milligrams (mg) | Eligible participants with symptomatic coronavirus disease 2019 (COVID-19) who were at risk of venous and arterial thrombotic complications, received rivaroxaban 10 mg, orally, once daily throughout the 35 days of double-blind treatment period along with ongoing standard of care medications for COVID-19 at the discretion of the treating physician. | 22 | 641 | OG000 |
| Group 2 | Placebo | Eligible participants with symptomatic COVID-19 who were at risk of venous and arterial thrombotic complications, received placebo matching to rivaroxaban, orally, once daily throughout the 35 days of double-blind treatment period along with ongoing standard of care medications for COVID-19 at the discretion of the treating physician. | 19 | 643 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants With Time to First Occurrence of Primary Efficacy Composite Endpoint
- Description
Number of participants with time to first occurrence of primary efficacy composite endpoint were reported. Time to first occurrence of primary efficacy composite endpoint is defined as time from randomization to first occurrence of any component of the primary endpoint. The components were: symptomatic venous thromboembolism (VTE), myocardial infarction (MI), ischemic stroke, acute limb ischemia, non-central nervous system (non-CNS) systemic embolization, all-cause hospitalization, and all-cause mortality.
- Time frame
- Up to Day 35
- Population
- Intent-To-Treat (ITT) analysis set included all randomized participants who provided informed consent.
Source ClinicalTrials.gov
Trial
- Title
A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection
- NCT number
- NCT04508023
- Phases
- PHASE3
- Conditions
- Coronavirus Disease 2019 (COVID-19)
- Interventions
- Rivaroxaban, Placebo, Standard of Care (SOC)
- Lead sponsor
- Janssen Research & Development, LLC
- Results first posted
- 2023-07-18
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04508023?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04508023-bf7c2edc